Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets

Simple item page
dc.contributor.authorPereira, Renato B.
dc.contributor.authorEvdokimov, Nikolai M.
dc.contributor.authorLefranc, Florence
dc.contributor.authorValentao, Patricia
dc.contributor.authorKornienko, Alexander
dc.contributor.authorPereira, David M.
dc.contributor.authorAndrade, Paula B.
dc.contributor.authorGomes, Nelson G. M
dc.date.accessioned2019-07-30T14:41:55Z
dc.date.available2019-07-30T14:41:55Z
dc.date.issued2019-06
dc.description.abstractThe role of the marine environment in the development of anticancer drugs has been widely reviewed, particularly in recent years. However, the innovation in terms of clinical benefits has not been duly emphasized, although there are important breakthroughs associated with the use of marine-derived anticancer agents that have altered the current paradigm in chemotherapy. In addition, the discovery and development of marine drugs has been extremely rewarding with significant scientific gains, such as the discovery of new anticancer mechanisms of action as well as novel molecular targets. Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer.
dc.description.departmentChemistry and Biochemistry
dc.formatText
dc.format.extent21 pages
dc.format.medium1 file (.pdf)
dc.identifier.citationPereira, R. B., Evdokimov, N. M., Lefranc, F., Valentão, P., Kornienko, A., Pereira, D. M., Andrade, P. B., & Gomes, N. G. M. (2019). Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. Marine Drugs, 17(6): 329.
dc.identifier.doihttps://doi.org/10.3390/md17060329
dc.identifier.urihttps://hdl.handle.net/10877/8416
dc.language.isoen
dc.publisherMultidisciplinary Digital Publishing Institute
dc.rights.holder© 2019 The Authors.
dc.rights.licenseThis work is licensed under a Creative Commons Attribution 4.0 International License.
dc.sourceMarine Drugs, 2019, Vol. 17, No. 6, Article, 329.
dc.subjecttrabectedin
dc.subjecteribulin
dc.subjectbrentuximab vedotin
dc.subjectplitidepsin
dc.subjectlurbinectedin
dc.subjectplinabulin
dc.subjectmarizomib
dc.subjectplocabulin
dc.subjectantibody drug conjugates
dc.subjectcytarabine
dc.titleMarine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
marinedrugs-17-00329-v3.pdf
Size:
543.28 KB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.54 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

College of Science and Engineering